Floatz logo

Denileukin Diftitox

Systemic Mastocytosis

M.D. Anderson Cancer Centerprotein_peptidePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Systemic Mastocytosis cohort.

Asset / SponsorPhaseRating
Imatinib
Novartis Pharmaceuticals
Phase 2B
Brentuximab Vedotin
Jason Robert Gotlib
Phase 2B
Avapritinib
Blueprint Medicines Corporation
Phase 2B
Ibrutinib
Jason Robert Gotlib
Phase 2CCC
Bezuclastinib
Cogent Biosciences, Inc.
Phase 2CCC

View all 15 →

Same molecule, other indications

Denileukin Diftitox is also rated in:

primary cutaneous T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
mycosis fungoidesDormant
B
Indicative ·
62 / 100
View asset →
Sezary syndromeDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →